Photo of Amy L. Billett,  MD

Amy L. Billett, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-5640
Fax: (617) 632-4811


amy_billett@dfci.harvard.edu

Amy L. Billett, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Associate Professor, Pediatrics, Harvard Medical School
  • Associate in Medicine, Hematology-Oncology, Boston Children's Hospital
  • Clinical Associate, Pediatrics, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

Our clinical research focuses on improving the long-term outcome for children with Hodgkin's disease. We also are involved in defining and measuring medication error, and developing systems to prevent it. Our other research interests include relapsed acute lymphoblastic leukemia (ALL) and chemotherapy-induced nausea and vomiting.

Publications

Powered by Harvard Catalyst
  • Croteau SE, Henderson ER, Billett AL, Gebhardt MC, Voss SD. Resolving bony abnormality evolves to diffuse large B-cell lymphoma. Pediatr Blood Cancer 2013; 60:E113-5. PubMed
  • Friedmann AM, Wolfson JA, Hudson MM, Weinstein HJ, Link MP, Billett A, Larsen EC, Yock T, Donaldson SS, Marcus K, Krasin MJ, Howard SC, Metzger ML. Relapse after treatment of pediatric Hodgkin lymphoma: outcome and role of surveillance after end of therapy. Pediatr Blood Cancer 2013; 60:1458-63. PubMed
  • Walsh KE, Roblin DW, Weingart SN, Houlahan KE, Degar B, Billett A, Keuker C, Biggins C, Li J, Wasilewski K, Mazor KM. Medication errors in the home: a multisite study of children with cancer. Pediatrics 2013; 131:e1405-14. PubMed
  • Gaur AH, Bundy DG, Gao C, Werner EJ, Billett AL, Hord JD, Siegel JD, Dickens D, Winkle C, Miller MR, . Surveillance of hospital-acquired central line-associated bloodstream infections in pediatric hematology-oncology patients: lessons learned, challenges ahead. Infect Control Hosp Epidemiol 2013; 34:316-20. PubMed
  • Kelly MS, Conway M, Wirth KE, Potter-Bynoe G, Billett AL, Sandora TJ. Microbiology and risk factors for central line-associated bloodstream infections among pediatric oncology outpatients: a single institution experience of 41 cases. J. Pediatr. Hematol. Oncol. 2013; 35:e71-6. PubMed
  • Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA 2012; 307:2609-16. PubMed
  • Feusner JH,Ritchey AK,Cohn SL,Billett AL. Management of tumor lysis syndrome: need for evidence-based guidelines. J Clin Oncol 2008; 26:5657-8; author reply 5658-9. PubMed
  • Donaldson SS, Link MP, Weinstein HJ, Rai SN, Brain S, Billett AL, Hurwitz CA, Krasin M, Kun LE, Marcus KC, Tarbell NJ, Young JA, Hudson MM. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007; 25:332-7. PubMed
  • Carpentieri SC, Waber DP, Pomeroy SL, Scott RM, Goumnerova LC, Kieran MW, Billett AL, Tarbell NJ. Neuropsychological functioning after surgery in children treated for brain tumor. Neurosurgery 2003; 52:1348-56; discussion 1356-. PubMed
  • Marcus KJ, Dutton SC, Barnes P, Coleman CN, Pomeroy SL, Goumnerova L, Billett AL, Kieran M, Tarbell NJ. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys 2003; 55:1182-5. PubMed
  • Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billett AL, Marcus KC, Hurwitz CA, Young JA, Tarbell NJ, Weinstein HJ. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol 2002; 20:3081-7. PubMed
  • LeClerc JM, Billett AL, Gelber RD, Dalton V, Tarbell N, Lipton JM, Barr R, Clavell LA, Asselin B, Hurwitz C, Schorin M, Lipshultz SE, Declerck L, Silverman LB, Cohen HJ, Sallan SE. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol 2002; 20:237-46. PubMed
  • Kim JY, Sutton ME, Lu DJ, Cho TA, Goumnerova LC, Goritchenko L, Kaufman JR, Lam KK, Billet AL, Tarbell NJ, Wu J, Allen JC, Stiles CD, Segal RA, Pomeroy SL. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999; 59:711-9. PubMed
  • Weisdorf DJ, Billett AL, Hannan P, Ritz J, Sallan SE, Steinbuch M, Ramsay NK. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 1997; 90:2962-8. PubMed
  • Tao ML, Barnes PD, Billett AL, Leong T, Shrieve DC, Scott RM, Tarbell NJ. Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome. Int J Radiat Oncol Biol Phys 1997; 39:579-87. PubMed
  • Billett AL, Sallan SE. Antiemetics in children receiving cancer chemotherapy. Support Care Cancer 1994; 2:279-85. PubMed
  • Billett AL, Kornmehl E, Tarbell NJ, Weinstein HJ, Gelber RD, Ritz J, Sallan SE. Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood 1993; 81:1651-7. PubMed
  • Billett AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 1992; 70:201-6. PubMed
  • Sallan SE, Niemeyer CM, Billett AL, Lipton JM, Tarbell NJ, Gelber RD, Murray C, Pittinger TP, Wolfe LC, Bast RC. Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol 1989; 7:1594-601. PubMed
Hide